Mesenchymal Stem Cells for COPD

Recruiting in Palo Alto (17 mi)

Overseen byJorge M Mallea, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Mayo Clinic

No Placebo Group

Trial Summary

What is the purpose of this trial?

This study is evaluating whether mesenchymal stem cells therapy may help improve lung function for individuals with chronic obstructive pulmonary disease.

Research Team

Jorge M Mallea, MD

Principal Investigator

Mayo Clinic

Eligibility Criteria

Adults with advanced COPD who've had a flare-up in the last year, have quit smoking for at least six months, and have specific lung function test results. They must not be pregnant or breastfeeding, have a history of certain diseases like cancer or autoimmune disorders, recent infections requiring antibiotics, or severe heart issues.

Inclusion Criteria

Age range: at least 18 years of age

You have not used any nicotine products for at least six months before joining the study.

You must have at least a score of 2 on the modified Medical Research Council (mMRC) scale.

See 13 more

Exclusion Criteria

Subject has or has had an active infection requiring systemic antibiotics within 12 weeks on enrollment in the study

Your body is very overweight (BMI over 35) or very underweight (BMI less than 16).

Subject is pregnant or breast-feeding

See 16 more

Treatment Details

Interventions

Mesenchymal Stem Cells (Stem Cell Therapy)

Trial OverviewThe trial is exploring the effects of mesenchymal stem cells on patients with advanced chronic obstructive pulmonary disease (COPD) to see if this therapy can improve their lung function and quality of life.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Subjects with Advanced Chronic Obstructive Pulmonary DiseaseExperimental Treatment1 Intervention

Subjects diagnosed with severe or very severe COPD will be infused intravenously with Mesenchymal Stem Cells (MSC)